Details for Patent: 11,458,041

Which drugs does patent 11,458,041 protect, and when does it expire?

Patent 11,458,041 protects DEXTENZA and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 11,458,041

Title:	Punctal plug and bioadhesives
Abstract:	The present disclosure provides devices and methods for the treatment of ophthalmological conditions such as dry eye. Among the devices provided are punctal plugs and devices for inserting punctal plugs. The punctal plugs may be shaped for insertion in the punctum and/or the canaliculus. They may also be coated with a bioadhesive. Methods for inserting the punctal plugs are provided, as well as methods for preparing bioadhesive-coated punctal plugs. A method is also provided to treat dryeye using a bioadhesive without use of a punctal plug.
Inventor(s):	Noah Silverberg, Mark Silverberg
Assignee:	Ocular Therapeutix Inc
Application Number:	US15/766,647
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 11,458,041

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ocular Therapeutix	DEXTENZA	dexamethasone	INSERT;OPHTHALMIC	208742-001	Nov 30, 2018		RX	Yes	Yes	11,458,041					TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
Ocular Therapeutix	DEXTENZA	dexamethasone	INSERT;OPHTHALMIC	208742-001	Nov 30, 2018		RX	Yes	Yes	11,458,041					TREATMENT OF OCULAR INFLAMMATION AND PAIN FOLLOWING OPHTHALMIC SURGERY

International Family Members for US Patent 11,458,041

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2017062770